Samyshkin Y - Search Results

1

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Lorusso D, Guy H, Samyshkin Y, Hawkes C, Estenson K, Coleman RL. Lorusso D, et al. Among authors: samyshkin y. Cancers (Basel). 2022 Mar 2;14(5):1285. doi: 10.3390/cancers14051285. Cancers (Basel). 2022. PMID: 35267593 Free PMC article. Review.

2

Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.

Nikolaou A, Ambavane A, Shah A, Ma W, Tosh J, Kapetanakis V, Willson J, Wang F, Hogea C, Gorsh B, Gutierrez B, Sapra S, Suvannasankha A, Samyshkin Y. Nikolaou A, et al. Among authors: samyshkin y. Expert Rev Hematol. 2021 Dec;14(12):1137-1145. doi: 10.1080/17474086.2021.1970522. Epub 2021 Sep 20. Expert Rev Hematol. 2021. PMID: 34465265

3

An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure.

Nikolaou A, Hogea C, Samyshkin Y, Maiese EM, Sansbury L, Oguz M, Cid-Ruzafa J, Kapoor R, Wang F. Nikolaou A, et al. Among authors: samyshkin y. Value Health. 2022 Dec;25(12):1977-1985. doi: 10.1016/j.jval.2022.05.011. Epub 2022 Aug 11. Value Health. 2022. PMID: 35963840 Free article.

4

Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.

Samyshkin Y, Guillermin AL, Best JH, Brunell SC, Lloyd A. Samyshkin Y, et al. J Med Econ. 2012;15 Suppl 2:6-13. doi: 10.3111/13696998.2012.708691. Epub 2012 Jul 16. J Med Econ. 2012. PMID: 22793669 Free article.

5

Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.

Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA. Guillermin AL, et al. Among authors: samyshkin y. J Med Econ. 2012;15(4):654-63. doi: 10.3111/13696998.2012.670677. Epub 2012 Mar 12. J Med Econ. 2012. PMID: 22369345 Free article.

6

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.

Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K. Hertel N, et al. Among authors: samyshkin y. Int J Chron Obstruct Pulmon Dis. 2012;7:183-99. doi: 10.2147/COPD.S29820. Epub 2012 Mar 19. Int J Chron Obstruct Pulmon Dis. 2012. PMID: 22500119 Free PMC article.

7

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.

Shah A, Tosh JC, Ambavane A, Nikolaou A, Hogea C, Samyshkin Y, Gorsh B, Maiese EM, Wang F. Shah A, et al. Among authors: samyshkin y. Clinicoecon Outcomes Res. 2021 Sep 10;13:789-800. doi: 10.2147/CEOR.S310619. eCollection 2021. Clinicoecon Outcomes Res. 2021. PMID: 34531667 Free PMC article.

8

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.

Samyshkin Y, Schlunegger M, Haefliger S, Ledderhose S, Radford M. Samyshkin Y, et al. Int J Chron Obstruct Pulmon Dis. 2013;8:79-87. doi: 10.2147/COPD.S37486. Epub 2013 Jan 30. Int J Chron Obstruct Pulmon Dis. 2013. PMID: 23386787 Free PMC article.

9

Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.

Samyshkin Y, Kotchie RW, Mörk AC, Briggs AH, Bateman ED. Samyshkin Y, et al. Eur J Health Econ. 2014 Jan;15(1):69-82. doi: 10.1007/s10198-013-0456-5. Epub 2013 Feb 8. Eur J Health Econ. 2014. PMID: 23392624 Free PMC article.

10

Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.

Guillermin AL, Samyshkin Y, Wright D, Nguyen T, Villeneuve J. Guillermin AL, et al. Among authors: samyshkin y. J Med Econ. 2011;14(2):207-16. doi: 10.3111/13696998.2011.561390. Epub 2011 Mar 2. J Med Econ. 2011. PMID: 21361858 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

31 results

Search Page